Racura Oncology Ltd (ASX:RAC)
Australia · Delayed Price · Currency is AUD 2.190
-0.050 (-2.23%)
Sep 2, 2026, 11:32 AM AEST
Racura Oncology Revenue
In the fiscal year ending June 30, 2026, Racura Oncology had annual revenue of 2.81M AUD, down -46.50%.
Revenue
2.81M
Revenue Growth
-46.50%
P/S Ratio
156.24
Revenue / Employee
n/a
Employees
n/a
Market Cap
439.19M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 2.81M | -2.44M | -46.50% |
| Jun 30, 2025 | 5.25M | 1.25M | 31.25% |
| Jun 30, 2024 | 4.00M | 869.09K | 27.73% |
| Jun 30, 2023 | 3.13M | 2.43M | 342.83% |
| Jun 30, 2022 | 707.81K | 320.42K | 82.71% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Clinuvel Pharmaceuticals | 94.02M |
| BLS Pharmaceuticals | 47.95M |
| Actinogen Medical | 12.67M |
| Starpharma Holdings | 12.67M |
| Orthocell | 11.41M |
| Clarity Pharmaceuticals | 10.53M |
| Dimerix | 6.35M |
| Tetratherix | 3.86M |
Racura Oncology News
- 6 days ago - Racura Oncology Annual report: H2 2026 - Filings
- 5 weeks ago - Racura Oncology Slides: Investor presentation - Filings
- 5 weeks ago - Racura Oncology Earnings release: Q4 2026 - Filings
- 4 months ago - Racura Oncology Earnings release: Q3 2026 - Filings
- 7 months ago - Racura Oncology Earnings release: Q2 2026 - Filings
- 10 months ago - Racura Oncology Slides: FY 2025 - Filings
- 10 months ago - Racura Oncology Earnings release: Q1 2026 - Filings
- 11 months ago - Racura Oncology Slides: Investor presentation - Filings